Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
Mahmud Mahamid1,3, Reuven Mader4, Rifaat Safadi1,2 1Liver Unit, Holy Family Hospital, Nazareth, Israel; 2Hadassah Medical Center, Jerusalem, Israel; 3Shaare Zedek Medical Center, Jerusalem, Israel; 4Rheumatology Unit, Ha’emek Medical Center, Afula, Israel Background: Elevation of liver enz...
Saved in:
Main Authors: | Mahamid M (Author), Mader R (Author), Safadi R (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2011-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tocilizumab in the treatment of rheumatoid arthritis and beyond
by: Shetty A, et al.
Published: (2014) -
Tocilizumab in the Treatment of Juvenile Rheumatoid Arthritis
by: V.V. Berejniy, et al.
Published: (2015) -
The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis
by: L. Riente
Published: (2011) -
Anakinra and hepatotoxicity in pediatric rheumatology: a case series
by: Frederico Rajão Martins, et al.
Published: (2023) -
Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
by: Yilmaz S, et al.
Published: (2013)